Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease

Area of Science:

• Cardiovascular Research
• Pediatric Immunology
• Hematology

Background:

• Platelet dynamics in Kawasaki disease (KD) remain poorly understood.
• The impact of antiplatelet therapy on KD progression requires further investigation.

Purpose of the Study:

• To elucidate platelet activation dynamics in acute-phase KD patients.
• To assess platelet-derived microparticles (PDMPs) as a marker of platelet activation in KD.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure PDMP levels in 18 acute KD patients.
• Blood samples were collected at multiple time points: before and after IVIG, and at 1, 2, and 3 months post-disease onset.
• Patient cohorts included those receiving oral aspirin with IVIG and those receiving oral aspirin alone.

Main Results:

• PDMP levels were significantly higher in acute KD patients compared to controls with febrile illnesses (P<0.01).
• Intravenous immunoglobulin (IVIG) significantly reduced PDMP levels in acute KD patients.
• PDMP levels did not decrease in patients not receiving IVIG.
• Eight patients experienced a rebound in PDMP levels after aspirin discontinuation.

Conclusions:

• Platelet activation is confirmed during the acute phase of Kawasaki disease.
• Antiplatelet therapy is crucial in managing KD.
• Platelet activation can persist for 2-3 months post-acute phase, indicating a need for individualized aspirin discontinuation timing.